Lund University Hospital

The rheumatology department at Lund University Hospital is conducting trials that aim to improve management of conditions such as fibromyalgia and other chronic pain disorders, focusing on new therapeutic approaches and patient‑centered outcomes.

• Novel biologic agents for pain modulation
• Autoantibody‑targeted therapies
• Rehabilitation and functional outcome studies
• Combination drug‑device interventions

These studies emphasize multidisciplinary collaboration and real‑world effectiveness, offering patients access to cutting‑edge treatments.

Research at the site targets a range of cancers, including small‑cell lung cancer, mantle cell lymphoma and testicular cancer, with the goal of testing innovative immunotherapy and targeted‑therapy combinations to enhance survival and quality of life.

• Immunotherapy plus chemotherapy regimens
• Molecular profiling for personalized therapy
• Adjuvant chemotherapy comparison studies
• Progression‑free survival endpoints

The oncology team works closely with surgeons and radiologists to integrate translational research into standard cancer care.

Trials focus on heart‑related conditions such as atrial fibrillation, acute myocardial infarction with cardiogenic shock and heart‑transplant recipients, evaluating strategies that reduce complications and improve organ function.

• Post‑surgical anticoagulation management
• Reduced noradrenaline protocols in shock
• Renal protection with dapagliflozin in transplant patients
• Advanced imaging for risk stratification

Collaboration between cardiology, transplant medicine and intensive‑care units strengthens the clinical relevance of these investigations.

The department explores surgical and post‑operative challenges, including liver tumor resections and esophageal atresia repair, aiming to reduce complications such as strictures and improve recovery.

• Intravenous lidocaine use in liver surgery
• Intralesional steroid injections to prevent esophageal strictures
• Monitoring liver regeneration biomarkers
• Nutritional support protocols after major abdominal procedures

These studies integrate surgical expertise with translational science to enhance patient outcomes.

Clinical work includes blood‑cancer investigations, covering diseases like acute myeloid leukemia, chronic myeloid leukemia and chronic lymphocytic leukemia, with a focus on novel combination regimens and molecular response tracking.

• Azacitidine‑based treatment strategies
• Low‑dose venetoclax combinations
• Deep molecular response assessment
• Patient‑reported quality‑of‑life measures

The trials leverage national registries to provide long‑term safety and efficacy data.

Innovative diagnostic tools and delivery methods are being evaluated, such as real‑time imaging and intralesional steroid injections for pediatric esophageal repair, to improve precision and safety of interventions.

• Ultrasound‑guided therapeutic procedures
• Novel drug‑delivery device testing
• Biomarker assays for early treatment response
• Cost‑effectiveness analyses of new technologies

These efforts support Lund University Hospital’s commitment to state‑of‑the‑art clinical research infrastructure.

The site also conducts studies that span multiple specialties, including reproductive health and rare inflammatory conditions such as VEXAS syndrome, aiming to broaden therapeutic options across patient groups.

• Immediate intrauterine device placement after medical abortion
• Azacitidine therapy for VEXAS syndrome
• Cross‑disciplinary safety monitoring frameworks
• Patient‑reported outcome collection across disease areas

This flexibility showcases the hospital’s ability to address emerging clinical needs through collaborative research.